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Abstract
Background: Simple biomarkers are required to identify TB in both HIV
2TB
+ and HIV
+TB
+ patients. Earlier studies have
identified the M. tuberculosis Malate Synthase (MS) and MPT51 as immunodominant antigens in TB patients. One goal of
these investigations was to evaluate the sensitivity and specificity of anti-MS and –MPT51 antibodies as biomarkers for TB in
HIV
2TB
+ and HIV
+TB
+ patients from a TB-endemic setting. Earlier studies also demonstrated the presence of these
biomarkers during incipient subclinical TB. If these biomarkers correlate with incipient TB, their prevalence should be higher
in asymptomatic HIV
+ subjects who are at a high-risk for TB. The second goal was to compare the prevalence of these
biomarkers in asymptomatic, CD4
+ T cell-matched HIV
+TB
2 subjects from India who are at high-risk for TB with similar
subjects from US who are at low-risk for TB.
Methods and Results: Anti-MS and -MPT51 antibodies were assessed in sera from 480 subjects including PPD
+ or PPD
2
healthy subjects, healthy community members, and HIV
2TB
+ and HIV
+TB
+ patients from India. Results demonstrate high
sensitivity (,80%) of detection of smear-positive HIV
2TB
+ and HIV
+TB
+ patients, and high specificity (.97%) with PPD
+
subjects and endemic controls. While ,45% of the asymptomatic HIV
+TB
2 patients at high-risk for TB tested biomarker-
positive, .97% of the HIV
+TB
2 subjects at low risk for TB tested negative. Although the current studies are hampered by
lack of knowledge of the outcome, these results provide strong support for the potential of these biomarkers to detect
incipient, subclinical TB in HIV
+ subjects.
Conclusions: These biomarkers provide high sensitivity and specificity for TB diagnosis in a TB endemic setting. Their
performance is not compromised by concurrent HIV infection, site of TB and absence of pulmonary manifestations in
HIV
+TB
+ patients. Results also demonstrate the potential of these biomarkers for identifying incipient subclinical TB in
HIV
+TB
2 subjects at high-risk for TB.
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Introduction
Over 90% of the ,8.8610
6 tuberculosis (TB) cases that occur
annually live in resource-constrained countries where TB is
endemic and the diagnosis is based on microscopic examination
of smears prepared directly from the patient specimens (mostly
sputum) for acid-fast bacilli (AFB) [1,2]. While microscopy
identifies the highly infectious multibacillary patients, its diagnostic
performance varies depending on the diligence and the work-load
of the microscopist, it requires multiple specimens (and patient
visits) which leads to significant drop-out of infectious patients, and
takes several days to provide results under programmatic
conditions [1]. As the HIV-epidemic has taken root in the TB-
endemic countries, the inadequacies of microscopy-based TB
diagnosis have been exacerbated since the immunosuppression of
cellular responses in the dually-infected patients results in
diminished cavity formation, and consequently, greater proportion
of both smear-negative TB and extrapulmonary TB (EPTB) [3].
Biomarkers for TB that can be adapted to robust, point-of-care
and affordable user-friendly formats that can replace the AFB
smear-based diagnosis and rapidly identify both HIV
2TB
+ and
HIV
+TB
+ patients are urgently required [3].
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were unsuccessful for decades [4] but promising antigens have been
identified in recent years [5,6,7,8,9,10,11,12,13,14]. Our labs have
used screening of immunoblots of 2-D fractionated Mycobacterium
tuberculosis (M. tb) culture-filtrate proteins [8,9,15], microarrays of M.
tb cytosolic and culture-filtrate proteins [16] and M. tb DNA
expression libraries [17,18] with sera from TB patients and M. tb-
infected animals at different stages of TB to identify several
immunodominant antigens. While some of the immunodominant
antigens (eg, 38kDa PhoS protein) are specific to cavitary TB
[6,8,19], others, such as the 81-kDa Malate Synthase (MS)
(Rv1837c) and the 29-kDa MPT51 (Rv3803c) elicit antibodies in
patients at different stages of clinical TB (smear-negative or positive
TB; non-cavitary or cavitary TB) and in different classes of TB
patients (HIV
2TB
+ or HIV
+TB
+) [8,9,20,21]. Moreover, retrospec-
tive stored sera that were obtained from HIV
+TB
+ patients during
the months prior to clinical manifestation of TB when they were
asymptomatic (subclinical TB) were demonstrated to contain
antibodies to these antigens [9]. Since these antibodies were not
detected in sera from PPD
2,P P D
+ or HIV
+TB
2 subjects, these
results suggested that the emergence of anti-MS and/or MPT51
antibodies could serve as biomarkers for incipient TB in asymptom-
atic HIV
+ subjects [6,9].
The currently available commercial antibody biomarkers fail to
provide acceptable sensitivity and specificity in TB-endemic
settings [4]. It is important that the new candidate biomarkers
be evaluated in TB-endemic countries before further development
is considered. The first goal of the current studies was to evaluate
the sensitivity and specificity of anti-MS and –MPT51 antibodies
as biomarkers for TB in HIV
2TB
+ and HIV
+TB
+ patients from a
TB-endemic setting. This has been done with subjects from India
which has an exceptionally high TB burden (250–300/100,000)
[22] and where 50–80% of the population is estimated to be
latently infected with M. tb [23,24].
As in other TB-endemic countries, 60–70% of the HIV
+ subjects
in India develop TB as their AIDS-defining opportunistic infection.
Since earlier studies with retrospective sera from HIV
+TB
+ patients
from the US indicated that anti-MS and/or MPT51 antibodies may
serve as biomarkers for incipient subclinical TB, this suggested that a
higher proportion of HIV
+ subjects at high-risk for TB would test
positive for these biomarkers compared to HIV
+ subjects at low-risk
for TB. The second goal of the current studies was to test this
hypothesis by comparing the prevalence of these biomarkers in
asymptomatic, CD4
+ Tc e l l - m a t c h e dH I V
+TB
2 subjects at low-risk
or high-risk for TB.
Materials and Methods
Study populations
Data reported in these studies are compiled from results obtained
with serum specimens tested over several years. Approval for the
studies was obtained from the Lala Ram Sarup Institute for
Tuberculosis and Respiratory Diseases (LRSI) ethics committee and
subsequentlyfrom theIndianCouncilforMedical Research(ICMR)
in2001. Patientsrecruited fromLRSIafter obtaining approvalsgave
written consent. Approval for the studies was also obtained from the
ethics committee at Post Graduate Institute for Medical Education
and Research (PGIMER), and subsequently from the ICMR in
2004. Aliquots of sera obtained from 40 HIV
2TB
+ patients and all
HIV
+TB
+ and HIV
+ subjects with oral consent (1998–2001) and
from 36 HIV
2TB
+ patients and 38 healthy subjects with written
consent (2004) for other investigations were tested for the current
studies after ICMR approvals were obtained. No information that
links individuals with serum specimens is available. The sera from
the HIV
+ patients and healthy subjects at the Veterans Affairs
Medical Center (VAMC) were obtained under consent forms
approved by the VAMC and/or New York University School of
Medicine (NYUSoM) IRB committees.
To evaluate the sensitivity and specificity of anti-MS and/or
MPT51 antibodies as biomarkers for TB in HIV
2TB
+ and
HIV
+TB
+ patients in a TB-endemic setting, sera from the
following groups of individuals were included in these studies.
a) PPD
+ and PPD
2 healthy subjects. (n=52) 35
HIV
2PPD
+ and 17 HIV
2PPD
2 individuals were included; 24
of 35 PPD
+ individuals were immigrants from TB-endemic
countries (India, China, Cameroon) working in the VAMC; 8
were bled within 2–12 weeks of arrival. Most of these individuals
were also BCG vaccinated. Eleven PPD
+ subjects, none of who
was BCG vaccinated were from US or Europe. Seven PPD
2
individuals were immigrants and 10 were US-born.
b) Healthy community controls. (HCC; n=38) Physicians,
scientists, nurses, technicians from PGIMER, with no risk for HIV
were enrolled as healthy community controls.
c). Non-HIV TB patients. (HIV
2TB
+; n=160): 138 TB
patientswereAFBsputumsmear-positive;124ofthesewere enrolled
from LSRI. Fourteen sputum smear-positive and 22 smear-negative
patients were from PGIMER. AFB cultures are not routinely
performed in PGIMER but the 22 smear-negative TB patients were
M. tb culture confirmed for the purposes of this study.
d). HIV-infected TB patients. (HIV
+TB
+; n=61). Of the
60 smear-positive HIV
+TB
+ patients enrolled at PGIMER, 50
presented with TB and were bled prior to initiation of anti-
retroviral therapy (ART) or anti-TB therapy (ATT). The
remaining 10 HIV
+TB
+ patients (who were not on ART)
developed TB during follow-up in the HIV clinic. Thirty two of
the 60 (53%) patients had normal chest X-rays, 12 (20%) showed
infiltration, 4 each (6.5%) had cavitary lesions or military TB, 3
(5%) showed signs of interstitial infiltration with PCP, 3 (5%) had
pleural effusions and 2 (2%) showed presence of nodular lesions.
Thirty four (57%) patients had EPTB (mostly lymph-node TB); of
these 31 had normal chest X-rays. The CD4
+ T cells in these
patients ranged from 18–548/ul.
Eleven HIV
+TB
2 patients progressed to HIV
+TB
+ during
follow-up. For 10 of these patients, 13 specimens obtained prior to
manifestation of TB (and 10 drawn at time of TB diagnosis) were
available. For the eleventh HIV
+TB
+ patient, 3 sera obtained prior
to diagnosis of TB were available but no serum specimen was
obtained at TB diagnosis. The sera obtained prior to manifestation
and diagnosis of TB is referred to as SCTB sera.
To compare the prevalence of anti-MS and/or MPT51 antibodies
in subjects who are at high-risk for TB with those at low risk for TB,
sera were obtained from the following groups of subjects:
e) HIV-infected subjects at high-risk for TB. (HIV
+TB
2,
HR; n=96). These were untreated HIV
+ patients from PGIMER
whose chest X-rays showed no abnormalities and had no clinical
symptoms suggestive of TB. Their CD4+ T cells ranged from 11–
1090/ul. PPD skin test or Quantiferon testing was not done in
these subjects but earlier studies have demonstrated a high
incidence (50–80%) of latent infection in the Indian population.
f). HIV-infected subjects at low-risk for TB. (HIV
+TB
2,
LR; n=73). These were HIV
+ asymptomatic individuals on ART
with no history or clinical suspicion of TB recruited from the
VAMC, NY. Their CD4
+ T cells ranged from 108–862/ul.
Antigens
Cloning and expression of the genes encoding MS and MPT51
and purification of the recombinant proteins was as previously
described [9].
Biomarkers for TB
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Recombinant purified MS or MPT51 were coated at 4 ug/ml
(50 ul/well) and the sera tested at 1:50 dilution for MS or 1:25
dilution for MPT51 [9]. A mixture of alkaline phosphatase-
conjugated Protein A (1:2000, Sigma, St. Louis, MO) and anti-IgA
(1:1000, Sigma) was used to detect the antigen-bound antibodies.
The Invitrogen Amplification System (Invitrogen, Carlsbad, CA)
was used for color development in a majority of the experiments
but during a time period when it was not available, PhosphoGLO
AP substrate (KPL, Gaithersburg, MD) was used. With the latter
substrate, after it’s addition to the ELISA-plate wells, the contents
of the wells were transferred to black plates (Microfluor 2 Black,
Thermo Milford, MA) and the plates read within 15 minutes in a
Lumimark Plus luminometer (BioRad, Hercules, CA). Comparative
studies with a defined set of serum specimens confirmed that the 2
substrates yielded same results (data not shown). The mean optical
density (490 nm) or the mean relative light units (RLU) obtained
with the PPD
+/PPD
2 healthy individuals + 3s t a n d a r dd e v i a t i o n s
(SD) was used as cut-off to determine positive reactivity. Each
specimen was tested 2–4 times; specimens which were consistently
positive, positive 2/3 or 3/4 times were considered positive. This
serum bank was collected over several years and the sera were tested
in batches as they were obtained (always with ,same numbers of
control sera); delta-OD or delta RLU (OD/RLU of specimen - cut-
off in that assay) was computed from different ELISA assays to
normalizeresults.TheELISA assayswere done inthe USlaboratory
in the context of the same control sera.
Statistical Analysis
Mann-Whitney test and the t-test were used to compare the
reactivity of sera from PPD
2 or PPD
+ healthy subjects with the
two antigens. The Pearson sample correlation was calculated to
determine the correlation between presence or absence of
antibodies and CD4
+T cell numbers in HIV
+TB
+ patients.
Results
Anti-MS and anti-MPT51 antibodies in PPD
+ and PPD
2
Healthy Control subjects
The reactivity of the sera from 17 PPD
2 healthy controls and
the 35 PPD
+ healthy controls with MS and MPT51 was compared
by ELISA (Fig 1). Sera from 5 AFB sputum smear-positive TB
patients known to be positive for reactivity with the 2 antigens was
used as positive controls for the ELISA [9]. When the OD values
for the 2 groups of healthy subjects were compared by Mann-
Whitney test (or the t-test) there was no significant difference
between them (p-value 0.5955 for MS and 0.5712 for MPT51).
Thus healthy subjects who may be latently infected with M. tb
and/or were BCG vaccinated lacked antibodies to the 2 antigens.
Anti-MS and anti-MPT51 antibodies in TB patients and
healthy controls
The mean OD of all 52 PPD
2/PPD
+ subjects plus 3 SD was
used as cut-off to determine positive responses in TB patients.
Based on this cut-off no HCC showed the presence of anti-MS
antibodies and 1/38 showed presence of anti-MPT51 antibodies
(specificity .97%). In contrast, anti-MS and anti-MPT51
antibodies were detected in 75% (103/138) and 59% (82/138)
of the smear-positive HIV
2TB
+ patients respectively (Fig 2A and
2B). Together, these biomarkers identified 80% (111/138) of the
smear-positive patients (Fig. 3A). Forty-four percent (9 of 22)
smear-negative TB patients also tested positive with either one or
both biomarkers (Fig 2A, 2B and 3A). Among the 60 smear-
positive HIV
+TB
+ patients, 47 (78%) had anti-MS and 41 (68%)
anti-MPT51 antibodies (Fig 2A and 2B); 82% (49/60) of the
patients exhibited presence of either one or both biomarkers in
their sera (Fig 3A).
The results from HIV
+TB
+ patients were analyzed based on
their CD4
+ T cell status. Of the 36 patients with CD4
+ T cells
,200/ul, 29 (81%) had anti-MS and 28 (77%) had anti-MPT51
antibodies; 31 of 36 (86%) patients tested positive for at-least one
of the 2 biomarkers (Fig 3B). Of the 22 HIV
+TB
+ patients with
CD4
+ T cell numbers between 201–400/ul, 18 (82%) possessed
anti-MS and/or MPT51 antibodies (Fig 3B). Two patients with
CD4
+ T cells .400/ul were excluded from this analysis. There
was no statistical correlation between the presence or absence of
antibodies and the CD4
+ T cell numbers when the Pearson sample
correlation was calculated (r=20.060).
Of 34 HIV
+TB
+ patients with EPTB, 29 had anti-MS and 23
had anti-MPT51 Abs (Fig 3C); either one or both biomarkers were
demonstrated in 85% (29/34) patients. Nineteen patients with
PTB had anti-MS and 18 anti-MPT51 antibodies; 20/26 (77%)
tested positive for either one or both biomarkers (Fig 3C). A vast
majority of the patients with normal chest X-rays (31/34) had
EPTB. Either one or both biomarkers were detected in 28 of 32
(87%) HIV
+TB
+ patients with normal chest X-rays and in 26/28
(89%) of patients with any radiological abnormality (data not
shown).
The retrospective specimens obtained 2–48 months prior to
clinical TB from the 11 HIV
+TB
+ patients were tested for these
biomarkers. For 8 of 11 patients, the retrospective specimens were
obtained within 6 months prior to TB diagnosis and retrospective
sera from 7/8 patients were antibody-positive (Table 1, Fig 4). For
3 patients the retrospective specimens were obtained 6–48 months
prior to TB, and these specimens tested negative (Table 1).
Together these results demonstrate that anti-MS and/or
MPT51 antibodies are present in sera from ,80% of the smear-
positive HIV
2TB
+ and HIV
+TB
+ patients but absent in sera from
the vast majority of PPD
+ subjects and endemic controls. The
sensitivity of the biomarkers is unaffected by the CD4
+ T cell loss
that accompanies progressive HIV-infection and is similar in
patients with PTB or EPTB. Finally, these biomarkers are present
in retrospective sera that were obtained from HIV
+ TB
+ patients
during 2–6 months prior to the clinical manifestation of TB.
Figure 1. Reactivity of sera with MS and MPT51: Sera from
HIV
2PPD
2 and HIV
2PPD
+ healthy subjects and TB patients were tested
for reactivity with MS (A) and MPT51 (B). Mean OD (optical
density)6standard deviation is depicted.
doi:10.1371/journal.pone.0002071.g001
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HIV
+TB
2 subjects at high-risk or low-risk for TB
The presence of these biomarkers was tested in asymptomatic
HIV
+TB
2 subjects from India who are at a high-risk for active
infection with M. tb (HIV
+TB
2, HR) and HIV
+TB
2 subjects from
the US who are a low risk for TB (HIV
+TB
2, LR). Sera from 40%
(38 of 96) of the HIV
+TB
2, HR subjects exhibited presence of
anti-MS and 32% (31 of 96) anti-MPT51 antibodies; either one or
both biomarkers were demonstrated in sera from 45% (43/96) of
these subjects (Fig 5A). In contrast, 97% (63/65) of the HIV
+TB
2,
LR subjects were negative for both biomarkers (Fig 5A).
There was an inverse correlation between the CD4
+ T cells and
presence of these biomarkers in sera from HIV
+TB
2, HR subjects.
Of the 96 HIV
+TB
2, HR subjects, 27 (28%) had CD4
+ cells
,200/ul and 16 (59%) were biomarker positive (Fig 5B); 36
subjects (38%) had CD4
+ T cells ranging from 201–400/ul and 19
(52%) were biomarker positive (Fig 5B), 33 (34%) subjects had
CD4
+ T cells .400/ul and 8 (24%) were positive (Fig 5B). Thus,
the proportion of biomarker-positive subjects increased with
Figure 2. Presence of anti-MS or anti-MPT51 antibodies in TB
patients: Sera from healthy PPD+/PPD
2 subjects, healthy community
controls (HCC) and TB patients was tested for presence of anti-MS (A) or
anti-MPT51 (B) antibodies. Delta OD (optical density) represents the OD
obtained with the individual serum specimen minus the mean OD plus
3 standard deviations obtained with the PPD
+/PPD
2 healthy subjects.
Filled symbols represent results from ELISA assays in which the
Invitrogen substrate was used. Delta RLU (relative light units) represents
relative light units obtained with the individual serum specimen minus
the mean RLU plus 3 standard deviations obtained with sera from PPD
+/
PPD
2 healthy subjects. Hollow symbols indicate results from ELISA
assays in which the PhosphoGLO AP substrate was used. Numbers in
parenthesis indicate number of subjects in each group.
doi:10.1371/journal.pone.0002071.g002
Figure 3. Anti-MS and/or anti-MPT51 antibodies as biomarkers
for TB in different categories of patients: Presence of the two
biomarkers in smear-positive HIV
2TB
+, smear-negative HIV
2TB
+ and
smear-positive HIV
+TB
+ patients (A). Presence of the biomarkers in
HIV
+TB
+ patients with CD4
+ T cell numbers ,200/ul or between 201–
400 (B). Presence of the biomarkers in HIV
+TB
+ patients with pulmonary
TB or extrapulmonary TB (C). In all figures, bars with diagonal lines
represent anti-MS antibodies, bars with dots represent anti-MPT51
antibodies and additive reactivity with both biomarkers is represented
by solid black bars. Numbers in parenthesis indicate number of subjects
in each group.
doi:10.1371/journal.pone.0002071.g003
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+ T cell numbers. There was no correlation
between these biomarkers and CD4
+ T cells in the HIV
+TB
2,L R
subjects (Fig 5C).
Thus, while anti-MS and/or MPT51 antibodies are rarely
detected in sera from asymptomatic HIV
+ subjects who are at a
low-risk for TB; these biomarkers are detected in sera from a
significant proportion of HIV
+ asymptomatic subjects who are at
the high risk for TB.
Discussion
These results demonstrate that anti-MS and/or -MPT51
antibodies are sensitive and specific biomarkers that identify
,80% of both HIV
2TB
+ and HIV
+TB
+ AFB smear positive
patients from a TB-endemic country. Importantly, the sensitivity
of these biomarkers is unaffected by factors that compromise the
performance of the currently used diagnostic tools in HIV
+
patients, i.e. reduced cavity formation, extrapulmonary location
and immunosuppression of cellular immune responses [25]. A
similar sensitivity of anti-MS antibodies was observed in HIV
+TB
+
patients from the US [9,21], and has been demonstrated in other
cohorts [11,12,13]. The high sensitivity provided by MPT51 in
HIV
+TB
+ patients has also been reported [26]. Thus, although
studies with some M. tb antigens suggested that antibody responses
are poor or absent in HIV
+TB
+ patients [27,28,29], our earlier
studies provided evidence for a defined subset of M. tb antigens
(including MS and MPT51) eliciting antibodies in these patients,
and several independent labs have now confirmed the potential of
anti-MS and-MPT51 antibodies as sensitive biomarkers for TB
diagnosis in these patients [9,11,12,13,21,26,30]. This is important
since the performance of biomarkers requiring intact cellular
responses (DTH or c-interferon) is likely to be compromised by the
dysregulated cellular immunity in the HIV
+ patients [31,32].
These biomarkers were absent in sera from .97% of the
endemic controls and in sera from .97% of the HIV
+ subjects
who are at a low-risk for TB. The high specificity in PPD
+ subjects,
HIV
+TB
2 patients, and patients with lung cancer, pneumonia and
non-TB lung infections has also been reported by other
investigators [11,12,26]. The absence of these biomarkers in sera
from PPD
+ subjects, and in healthy subjects from India and from
other TB endemic countries confirms the correlation of their
presence with active infection with M. tb. MS is an enzyme of the
Figure 4. Presence of anti-MS and anti-MPT51 antibodies during subclinical TB: Presence of the two biomarkers in retrospective sera
obtained during the months prior to manifestation of clinical TB in 4 HIV
+TB
+ patients is shown. Time 0 represents the time point at which clinical TB
was diagnosed; negative values refer to months preceding time 0. Delta OD (optical density) represents the OD obtained with the individual serum
specimen minus the mean OD plus 3 standard deviations obtained with the PPD
+/PPD
2 healthy subjects in the ELISA. For patient depicted in ‘D’, no
specimen was obtained at time of clinical diagnosis of TB.
doi:10.1371/journal.pone.0002071.g004
Table 1. Presence of anti-MS &/or –MPT51 antibodies during
SCTB in HIV
+TB
+ patients
PATIENT AT –TB SCTB
TIME BETWEEN SCTB
SPECIMEN & TB (MONTHS)
1 Positive Positive 2
2 Serum NA Positive 3
3 Positive Positive 3
4 Positive Positive 3
5 Positive Positive 4
6 Positive Positive 4
7 Positive Positive 5
8 Positive Negative 6
9 Positive Negative 7
10 Positive Negative 13
11 Positive Negative 48
NA: Not available
doi:10.1371/journal.pone.0002071.t001
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tion of M. tb [33]. Also, the M. tb MS has adapted to become a
secreted and surface-localized laminin-binding adhesin that
enhances the adherance of M. tb to pulmonary epithelial cells
[34]. These roles in intracellular survival and in pathogenesis
provide an explanation for the expression of MS (and therefore
presence of anti-MS antibodies) when active bacterial replication is
ongoing in vivo. MPT51 is also an adhesin of M. tb, likely expressed
during active replication of the bacteria, as suggested by its
presence in culture filtrates of M. tb [8]. The absence of these
biomarkers in sera from healthy PPD
+ subjects and from BCG-
vaccinated subjects indicates that immunostimulatory levels of the
2 proteins are achieved in vivo only during active bacterial
replication.
Although a sensitivity of ,80% is not sufficient to replace
microscopy, no other biomarkers that provide this high sensitivity
in smear positive HIV
2TB
+ as well as HIV
+TB
+ patients, and can
identify both pulmonary and extrapulmonary TB even when the
CD4
+ T cells have been significantly diminished in the latter
subjects have been reported [10,30]. MS and MPT51 are 2 of the
12 immunodominant M. tb antigens that elicit antibodies in both
HIV
2TB
+ and HIV
+TB
+ patients [8] and it is likely that inclusion
of one or two additional antigens from this subset will further
enhance the sensitivity to levels (90–95%) that are required of any
test that can replace microscopy [35]. Several additional novel
immunodominant antigens that were identified in our studies are
currently under investigation [16,17].
Anti-MS and/or MPT51 antibodies were also detected in sera
from ,45% of the HIV
2TB
+ AFB smear-negative patients, none
of who would be identified by microscopy. These results are
similar to those reported earlier with smear-negative HIV
2TB
+
patients from the US [21]. Thus, at the current performance level,
in a setting where 40% of the patients present with smear-negative
TB, these biomarkers would identify 66% of all TB cases,
compared to 60% being recognized by the smear test alone. In this
regard, although no smear-negative HIV
+TB
+ patients were tested
in the current studies; we have earlier demonstrated the presence
of these biomarkers in sera from ,80% of the smear-negative
HIV
+TB
+ patients [9,21]. The ability to detect patients with
smear-negative TB, and especially the high sensitivity in smear-
negative HIV
+TB
+ patients is important since concurrent HIV-
infection reduces pulmonary cavitation and sputum bacillary load
while accelerating the progression of TB [3,22,25,36]. The higher
sensitivity of these biomarkers in smear-negative HIV
+TB
+
patients is likely related both to a greater in vivo bacterial burden
as well as the generalized activation of B cell responses, including
the antigen-specific B cells, caused by HIV-infection [37,38,39].
As was reported with retrospective sera from US HIV
+TB
+
patients [6,9], these biomarkers were also demonstrated in the
retrospective sera obtained 2–6 months prior to TB diagnosis from
HIV
+TB
+ patients from India. Given the slow generation time of
M. tb, the in vivo replication of bacteria would be expected to be
initiated several weeks/months prior to the bacterial burden
reaching levels that are detectable by conventional means. The
ability of the immune system to detect the in vivo replication
provides an important tool for detection of active infection while it
is sub-clinical. Interestingly, the biomarkers were detected in sera
that were obtained ,6 months (or less) prior to clinical TB; the
period of incipient TB has been estimated to be 2–9 months in
HIV
+ subjects in other studies [40].
Approximately 75–80% of the millions of HIV-infected patients
in sub-Saharan Africa and Southeast Asia are co-infected with M.
tb, and as a result 50–70% of the HIV
+ subjects in these countries
develop TB [22,40,41]. This is in contrast to the US where even
before the availability of ART, only 3–4% of the HIV
+ patients
developed TB. Recent studies from other TB endemic countries
(Tanzania, South Africa, and Peru) have reported that passive case
finding fails to recognize a significant proportion of HIV
+TB
+
Figure 5. Presence of anti-MS and/or anti-MPT51 antibodies in
HIV
+TB
2 subjects at high-risk or low-risk for TB: Sera from
healthy PPD
+/PPD
2 subjects, asymptomatic HIV
+TB
2 subjects at high-
risk for TB (HR) and asymptomatic HIV
+TB
2 subjects at low-risk (LR) for
TB was tested for presence of anti-MS and -MPT51 antibodies (A).
Presence of these biomarkers in sera from HIV
+TB
2, HR subjects with
different CD4
+ T cell numbers (B), and in sera from HIV
+TB
2, LR subjects
with different CD4
+ T cell numbers (C). In all figures, bars with diagonal
lines represent anti-MS and bars with dots represent anti-MPT51
antibodies. Additive reactivity of both biomarkers is represented by
solid black bars. Numbers in parenthesis indicate number of subjects in
each group.
doi:10.1371/journal.pone.0002071.g005
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MPT51 Abs as biomarkers for TB in paucibacillary HIV
+TB
+
patients [9,21], and their presence in retrospective sera from
HIV
+TB
+ patients [9], we hypothesized that a higher proportion
of HIV
+TB
2 subjects at high-risk for TB will test positive for these
biomarkers as compared to HIV
+TB
2 subjects at low-risk for TB.
When CD4
+ T cell-matched asymptomatic HIV
+TB
2 HR
subjects from India and HIV
+TB
2 LR subjects from the US
were compared, ,45% of the former and ,5% of the latter tested
biomarker positive. The risk for TB increases as the T-cell
immunity wanes, and as expected, the proportion of biomarker-
positive HIV
+TB
2 HR subjects increased with decreasing CD4
+ T
cells. Although these cross-sectional studies are hampered by the
lack of knowledge of the final outcome, these results suggest the
presence of significant unrecognized TB in the HIV
+ subjects from
this endemic setting. It is likely that a proportion of the biomarker-
positive HIV
+TB
2, HR subjects would have been identified had
cultures been performed while others had truly incipient TB.
Interestingly, in a recent pilot study from Gugulethu township in
Cape town in which nebulized induced sputum specimens
obtained from 140 consecutively enrolled HIV
+ patients with
advanced immunodeficiency were tested using fluorescence
microscopy and automated liquid culture (MGIT-960,Becton
Dickinson, USA), 30% of the patients yielded positive M. tb
cultures (Dr. Stephen D. Lawn: personal communication).
Prospective studies to evaluate the predictive potential of these
biomarkers for TB, and for discriminating between truly latent
and incipient subclinical TB in HIV
+ subjects are planned. The
accurate identification of paucibacillary as well as incipient TB will
impact clinical decisions on treatment (INH prophylaxis versus
multidrug therapy) and time of ART initiation. Also, early
treatment of active TB may slow progression of HIV-infection.
The results of the current studies demonstrate the potential of
anti-MS and –MPT51 as biomarkers both for diagnosis of TB and
for detection of incipient M. tb infection in HIV
+ patients in a TB-
endemic setting. Although the sensitivity of diagnosis needs to be
enhanced, and the final panel of selected antigens will have to be
adapted to rapid formats, the current studies provide encouraging
results for feasibility of the development of a rapid, simple and
accurate test for TB diagnosis.
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